US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

21.88 +0.01 (+0.05%)
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Collegium Pharmaceutical, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Collegium's Revenue Outlook And CNS Expansion Signal Undervalued Opportunity, Says Needham ↗
Needham analyst upgrades Collegium Pharmaceutical to Buy with a $46 target, citing strong 2025 guidance, growth potential, and undervaluation. 
Via Benzinga
News headline image
Collegium Provides 2025 Financial Guidance and Business Update
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Participate in Upcoming Investor Conferences
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Reports Record Third Quarter 2024 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
A Preview Of Collegium Pharmaceutical's Earnings ↗
 
Via Benzinga
News headline image
The Analyst Landscape: 4 Takes On Collegium Pharmaceutical ↗
 
Via Benzinga
News headline image
The Analyst Verdict: Collegium Pharmaceutical In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings tomorrow after the bell. Here’s what to look for. 
Via StockStory
News headline image
Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Appoints Nancy S. Lurker to its Board of Directors
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Appoints Vikram Karnani as Chief Executive Officer
Vikram Karnani is a Proven Industry Leader with Extensive Experience Growing Commercial Biopharmaceutical Businesses 
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
S&P Global To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
Topics Stocks
News headline image
Collegium Completes Acquisition of Ironshore Therapeutics
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again? ↗
Dr. Reddy's Labs sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
News headline image
Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Organon Stock Sees Relative Strength Rating Rise To 91 ↗
On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before. 
Via Investor's Business Daily
News headline image
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold ↗
On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier. 
Via Investor's Business Daily
News headline image
COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Beats Revenue for Q2 2024 ↗
COLL stock results show that Collegium Pharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Collegium Reports Second Quarter 2024 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
In a market where value is scarce, NASDAQ:COLL offers a refreshing opportunity with its solid fundamentals. ↗
COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
News headline image
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
NASDAQ:COLL is an undervalued gem with solid fundamentals. ↗
COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
News headline image
Dr. Reddy's Labs Stock Sees Improved Technical Strength ↗
On Friday, Dr. Reddy's Labs ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 76. 
Via Investor's Business Daily
News headline image
7 Biotech Stocks to Buy on the Dip: June 2024 ↗
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace
News headline image
NASDAQ:COLL appears to be flying under the radar despite its strong fundamentals. ↗
COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) is an undervalued gem with solid fundamentals. 
Via Chartmill
News headline image
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >